TNDM240719P47500
- 8.05
- +0.05+0.63%
Tandem Diabetes Care Newsroom
Tandem Diabetes Care Analyst Ratings
Strong Market Reclaim and Innovative Pipeline Underpin Buy Rating for Tandem Diabetes Care
Tandem Diabetes Care Analyst Ratings
Redburn Atlantic Initiates Coverage On Tandem Diabetes Care With Buy Rating, Announces Price Target of $60
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Lake Street: Maintains Tandem Diabetes Care (TNDM.US) rating, adjusted from buy to buy rating, and adjusted target price from $60.00 to $75.00.
Lake Street Maintains Buy on Tandem Diabetes Care, Raises Price Target to $75
Tandem Diabetes Care Analyst Ratings
Tandem Diabetes Care Inc: Stifel increases target price from $45 to $55
Analysts' Opinions Are Mixed on These Healthcare Stocks: Omnicell (OMCL), Tandem Diabetes Care (TNDM) and Amgen (AMGN)
Tandem Diabetes Care Analyst Ratings
Barclays Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)
Tandem Diabetes Care Analyst Ratings
UBS Adjusts Price Target on Tandem Diabetes Care to $40 From $28, Maintains Neutral Rating
Piper Sandler: Reiterates the Tandem Diabetes Care (TNDM.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $35.00 to $50.00.
Piper Sandler Reiterates Overweight on Tandem Diabetes Care, Raises Price Target to $50
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Castle Biosciences (CSTL)
Tandem Diabetes Care (TNDM) Gets a Buy From Piper Sandler
Tandem Diabetes Care Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Eli Lilly & Co (LLY)